Hematopoiesis News 7.28 July 19, 2016 | |
| |
TOP STORYNew Signaling Pathway for Programmed Cell Death Identified in Leukemia Cells Acute myeloid leukemia is triggered by pathological alterations of bone marrow cells, in which, in addition, an important mechanism is out of action: these cells do not die when they are damaged. Researchers have now discovered a molecular signaling pathway for self-destruction that is suppressed in leukemia cells. [Press release from Technical University of Munich discussing online prepublication in Cancer Cell] Press Release | Abstract | Graphical Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Scientists showed that ectopic expression of a single microRNA, miR-125a, in purified murine and human multipotent progenitors resulted in increased self-renewal and robust long-term multi-lineage repopulation in transplanted recipient mice. [Cell Stem Cell] Abstract | Graphical Abstract | Press Release | Video Developmental Regulation of Myeloerythroid Progenitor Function by the Lin28b-let-7-Hmga2 Axis Investigators found that expression of the heterochronic factor Lin28b decreases in common myeloid progenitors during hematopoietic maturation to adulthood in mice. [J Exp Med] Abstract Leukemia Cell of Origin Identified by Chromatin Landscape of Bulk Tumor Cells Scientists used a well-defined model of MLL-rearranged acute myeloid leukemia (AML) to demonstrate that transforming hematopoietic stem cells and multipotent progenitors results in more aggressive AML than transforming committed progenitor cells. [Nat Commun] Full Article To investigate the clinicopathological impact of programmed cell death ligand 1 (PD-L1) expression in adult T-cell leukemia/lymphoma (ATLL), investigators performed PD-L1 immunostaining in 135 ATLL biopsy samples. [Blood] Abstract tfec Controls the Hematopoietic Stem Cell Vascular Niche during Zebrafish Embryogenesis Investigators identified tfec, a transcription factor from the mitf family, which is highly enriched in caudal endothelial cells at the time of hematopoietic stem cell colonization in the caudal hematopoietic tissue. [Blood] Abstract Researchers describe a good manufacturing practice-compatible, feeder-free and serum-free method to produce large numbers of erythroid cells from human pluripotent stem cells, either embryonic or induced. [Stem Cells Transl Med] Abstract | Full Article CLINICAL RESEARCHIn this multicenter, double-blind, randomized controlled trial, researchers investigated the incidence and severity of chronic graft-versus-host disease among patients, and the changes in T, B, and natural killer cells after the repeated infusion of mesenchymal stromal cells. [J Clin Oncol] Full Article Investigators presented five-year, end-of-study results from the pivotal Phase II trial of brentuximab vedotin in patients with relapsed/refractory Hodgkin lymphoma after failed hematopoietic autologous stem cell transplantation. [Blood] Abstract | Press Release Researchers report the outcomes of patients with multiple myeloma with and without TP53 deletion who underwent immunomodulatory drug and/or proteasome inhibitor induction followed by autologous hematopoietic stem cell transplant. [Am J Hematol] Abstract | |
| |
REVIEWSAging of Hematopoietic Stem Cells: DNA Damage and Mutations? The authors discuss the DNA damage theory of hematopoietic stem cells (HSCs) aging in the light of novel mechanisms of aging of HSCs. [Exp Hematol] Abstract | Full Article Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.
| |
INDUSTRY NEWSPluristem Advances Its U.S. FDA Trial in Hematologic Indication Pluristem Therapeutics Inc. announced it has advanced its Phase I trial of PLX-R18 cells to treat insufficient hematopoietic recovery following hematopoietic cell transplantation by contracting with a leading global clinical research organization. [Pluristem Therapeutics Inc. (GlobeNewswire)] Press Release Damon Runyon Cancer Research Foundation Awards over $4 Million to 10 Top Clinical Investigators The Damon Runyon Cancer Research Foundation named seven new Damon Runyon Clinical Investigators at its spring 2016 Clinical Investigator Award Committee review. The recipients of this prestigious three-year award are outstanding early career physician-scientists conducting patient-oriented cancer research at major research centers under the mentorship of the nation’s leading scientists and clinicians. [Damon Runyon Cancer Research Foundation] Press Release | |
From our sponsor: Learn about applications of ALDHbr cells in regenerative medicine. Watch the video.
| |
POLICY NEWSDrugs Watchdog Thwarting UK Progress in Stem Cell Therapy, Report Says Britain’s hopes of leading the world in revolutionary therapies that regenerate damaged body parts are under threat because the NHS drugs watchdog cannot properly evaluate them, a report says. [The Guardian] Editorial | Report Science’s Status Shifts in New Brexit Government Three weeks after UK voters chose to leave the European Union, the country has a new prime minister, Theresa May — and a revamped administration that is poised to change science’s place in government. [Nature News] Editorial Science under Siege: How Venezuela’s Economic Crisis Is Affecting Researchers The political and economic crisis in Venezuela continues to worsen. As the price of oil — the country’s major export — has fallen, Venezuela has struggled to pay for imported goods while maintaining socialist economic policies put in place by former president Hugo Chávez. [Nature News] Editorial A Week of Political Bloodletting, but U.K. Science Minister Keeps His Job For researchers worried about the future of science in the United Kingdom, the news was something to hold onto. Jo Johnson announced he will remain as science minister, despite a massive shakeup of the government cabinet. [ScienceInsider] Editorial
| |
EVENTSNEW Cancer Stem Cell Conference 2016 Visit our events page to see a complete list of events in the hematopoiesis community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Scientist – Hemato-Oncology and Molecular Genetics (Helmholtz Association) Scientist – Hematology (STEMCELL Technologies Inc.) Technical Sales Representative (STEMCELL Technologies Inc.) Assistant Member Faculty – PlatinumImmunotherapy (Fred Hutchinson Cancer Research Center) Postdoctoral Fellow – Tumor Microenvironment and Cancer Stem Cells (Duke University) Postdoctoral Fellow – Characterizing and Targeting Cancer Stem Cells (City of Hope) Cytogenetics Laboratory Supervisor (Fred Hutchinson Cancer Research Center) Postdoctoral Fellow – Hematopoietic Stem Cell Biology (Novartis) Research Assistants and Associates – Leukemia and Stem Cell Biology (King’s College London) Postdoctoral Fellow – Leukemia Lymphoma (Emory University) Research Technician – Hematopoietic Stem Cell Biology (Fred Hutchinson Cancer Research Center) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Hematopoiesis News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|
Home Hematopoiesis News Volume 7.28 | Jul 19 2016